Age plays a significant role in how melanoma progresses and how the body’s immune system responds to the disease, according to new findings from French researchers.
The study, published in a leading dermatology journal, reveals that older patients with melanoma tend to experience faster tumor growth and a weaker immune response compared to younger individuals. Researchers observed that aging affects not only the behavior of cancer cells but too the functionality of immune cells tasked with recognizing and attacking them.
Data showed that in patients over 65, melanoma tumors were more likely to invade deeper layers of the skin and spread to lymph nodes at an earlier stage. At the same time, key immune markers — including T-cell activity and interferon signaling — were notably diminished in this age group.
“These results suggest that the immune system’s ability to control melanoma declines with age, which may help explain why older adults often face poorer outcomes,” said one of the study’s lead authors.
The findings highlight the need for age-specific approaches in both melanoma screening and treatment. Experts say that understanding how aging influences cancer immunity could improve the effectiveness of immunotherapies, which rely on stimulating the body’s own defenses.
While immunotherapy has transformed melanoma care in recent years, its success varies across age groups. This research may help clinicians better predict which patients are likely to benefit and guide the development of tailored strategies for older populations.
Public health officials note that melanoma rates continue to rise globally, particularly among older adults. With the U.S. Population aging, insights into age-related immune changes could become increasingly essential for prevention, early detection and treatment planning.
The study reinforces the importance of regular skin checks, especially for individuals over 50, and underscores the value of ongoing research into how biological aging interacts with cancer and immune function.
